FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1523733420> ?p ?o ?g. }

• W1523733420 endingPage "14" @default.
• W1523733420 startingPage "805" @default.
• W1523733420 abstract "The expression of Bcl-2, Bcl-X, Mcl-1, and Bax was examined by immunohistochemical methods in 93 tumors of nervous system origin, including 49 gliomas (30 astrocytomas and 19 glioblastoma multiforme (GMs)), 16 medulloblastomas (MBs), 19 neuroblastomas (NBs; 9 undifferentiated and 10 differentiated), and 9 miscellaneous neuroectodermal neoplasms. Among the 49 gliomas, immunopositivity (defined as > or = 10%) was observed for Bcl-2 in 45 (92%), Bcl-X in 48 (98%), Mcl-1 in 49 (100%), and Bax in 48 (98%) of 49 specimens. In 11 (37%) of 30 astrocytomas (WHO grades I to III), the tumor specimens were composed predominantly of malignant cells with strong-intensity Bcl-2 immunostaining, whereas none of the 19 GMs (WHO grade IV) exhibited strong-intensity Bcl-2 immunoreactivity (P = 0.001). Similarly, Mcl-1 immunointensity was strong in 15 (50%) of 30 astrocytomas, compared with only 2 (11%) of 19 GMs (P = 0.005). The percentage of Mcl-1-immunopositive tumor cells was also higher in astrocytomas than GMs (P < 0.002). Thus, contrary to a priori expectations, the expression of the anti-apoptotic proteins Bcl-2 and Mcl-1 was significantly higher in astrocytomas than in GMs. Of the 16 MBs, immunopositivity was found for Bcl-2 in 4 (25%), Bcl-X in 9 (56%), Mcl-1 in 8 (50%), and Bax in 16 (100%) of the cases. The intensity of immunostaining was strong for Bcl-2 in only 1 (6%) specimen, for Bcl-X in 3 (19%), and for Mcl-1 in 2 (12.5%), in contrast to Bax immunostaining, which was strong in 12 (75%) tumors. Significantly higher percentages of Bax-immunopositive tumor cells were also found in MBs, compared with Bcl-2, Bcl-X, and Mcl-1 (P < 0.0001). All 19 NBs were immunopositive for Bcl-2, Bcl-X, Mcl-1, and Bax. Higher percentages of Bcl-X- and Mcl-1-immunopositive tumor cells were observed in well differentiated tumors (P = 0.04 and 0.004, respectively). The intensity of Mcl-1 immunostaining was also generally higher in differentiated than undifferentiated NBs (strong immunointensity in 7 of 10 versus 0 of 9; P = 0.002). Conversely, strong-intensity Bax immunostaining was associated with undifferentiated histology (5 of 9 (56%) versus 1 of 10 (10%); P = 0.03). Taken together, these findings begin to delineate trends in the regulation of the relative levels of the Bcl-2 family proteins, Bcl-2, Bcl-X, Mcl-1, and Bax in gliomas, MBs, NBs, and some of their histological subtypes. The suggestion that expression of some of these Bcl-2 family genes may be differentially regulated in association with tumor progression and differentiation provides insights into the diverse biology and clinical behavior of these tumors of nervous system origin." @default.
• W1523733420 created "2016-06-24" @default.
• W1523733420 creator A5000848809 @default.
• W1523733420 creator A5010767525 @default.
• W1523733420 creator A5015647663 @default.
• W1523733420 creator A5041051444 @default.
• W1523733420 creator A5059438505 @default.
• W1523733420 creator A5072504891 @default.
• W1523733420 creator A5081985168 @default.
• W1523733420 date "1997-03-01" @default.
• W1523733420 modified "2023-09-23" @default.
• W1523733420 title "Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin." @default.
• W1523733420 cites W131994123 @default.
• W1523733420 cites W1481978338 @default.
• W1523733420 cites W1501414399 @default.
• W1523733420 cites W1542447612 @default.
• W1523733420 cites W154264227 @default.
• W1523733420 cites W1561506007 @default.
• W1523733420 cites W1572034293 @default.
• W1523733420 cites W1598719623 @default.
• W1523733420 cites W1878608668 @default.
• W1523733420 cites W1926885922 @default.
• W1523733420 cites W1962741441 @default.
• W1523733420 cites W1967304777 @default.
• W1523733420 cites W1982784171 @default.
• W1523733420 cites W1983099375 @default.
• W1523733420 cites W2000894919 @default.
• W1523733420 cites W2006804535 @default.
• W1523733420 cites W2008597649 @default.
• W1523733420 cites W2016914965 @default.
• W1523733420 cites W2019572526 @default.
• W1523733420 cites W2020721942 @default.
• W1523733420 cites W2028703351 @default.
• W1523733420 cites W2030312997 @default.
• W1523733420 cites W2048428832 @default.
• W1523733420 cites W2051219590 @default.
• W1523733420 cites W2058591356 @default.
• W1523733420 cites W2063176993 @default.
• W1523733420 cites W2080391833 @default.
• W1523733420 cites W2083140708 @default.
• W1523733420 cites W2086371845 @default.
• W1523733420 cites W2089883223 @default.
• W1523733420 cites W2092589738 @default.
• W1523733420 cites W2126699849 @default.
• W1523733420 cites W2132478086 @default.
• W1523733420 cites W2134979684 @default.
• W1523733420 cites W2137022580 @default.
• W1523733420 cites W2146320943 @default.
• W1523733420 cites W2152943473 @default.
• W1523733420 cites W2154745705 @default.
• W1523733420 cites W2162522735 @default.
• W1523733420 cites W2165278466 @default.
• W1523733420 cites W2169495754 @default.
• W1523733420 cites W2171725581 @default.
• W1523733420 cites W2172072395 @default.
• W1523733420 cites W2188651990 @default.
• W1523733420 cites W2189959642 @default.
• W1523733420 cites W2259568108 @default.
• W1523733420 cites W2275275778 @default.
• W1523733420 cites W2401060698 @default.
• W1523733420 cites W4211045864 @default.
• W1523733420 cites W4240678817 @default.
• W1523733420 cites W97746810 @default.
• W1523733420 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1857882" @default.
• W1523733420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9060818" @default.
• W1523733420 hasPublicationYear "1997" @default.
• W1523733420 type Work @default.
• W1523733420 sameAs 1523733420 @default.
• W1523733420 citedByCount "50" @default.
• W1523733420 countsByYear W15237334202013 @default.
• W1523733420 countsByYear W15237334202014 @default.
• W1523733420 countsByYear W15237334202015 @default.
• W1523733420 countsByYear W15237334202016 @default.
• W1523733420 countsByYear W15237334202017 @default.
• W1523733420 countsByYear W15237334202018 @default.
• W1523733420 countsByYear W15237334202019 @default.
• W1523733420 countsByYear W15237334202020 @default.
• W1523733420 countsByYear W15237334202022 @default.
• W1523733420 crossrefType "journal-article" @default.
• W1523733420 hasAuthorship W1523733420A5000848809 @default.
• W1523733420 hasAuthorship W1523733420A5010767525 @default.
• W1523733420 hasAuthorship W1523733420A5015647663 @default.
• W1523733420 hasAuthorship W1523733420A5041051444 @default.
• W1523733420 hasAuthorship W1523733420A5059438505 @default.
• W1523733420 hasAuthorship W1523733420A5072504891 @default.
• W1523733420 hasAuthorship W1523733420A5081985168 @default.
• W1523733420 hasConcept C142724271 @default.
• W1523733420 hasConcept C204232928 @default.
• W1523733420 hasConcept C2778227246 @default.
• W1523733420 hasConcept C2778880634 @default.
• W1523733420 hasConcept C4224716 @default.
• W1523733420 hasConcept C502942594 @default.
• W1523733420 hasConcept C71924100 @default.
• W1523733420 hasConcept C86803240 @default.
• W1523733420 hasConceptScore W1523733420C142724271 @default.
• W1523733420 hasConceptScore W1523733420C204232928 @default.
• W1523733420 hasConceptScore W1523733420C2778227246 @default.
• W1523733420 hasConceptScore W1523733420C2778880634 @default.

• next